-
公开(公告)号：US11529362B2
公开(公告)日：2022-12-20
申请号：US16817683
申请日：2020-03-13
IPC分类号： A61K31/675 , A61K31/496 , A61K9/08 , A61K9/00 , A61K9/19 , A61K47/02 , A61K47/18 , A61K47/26 , A61K31/473 , A61P1/08
摘要： Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
-
公开(公告)号：US20180194788A1
公开(公告)日：2018-07-12
申请号：US15874325
申请日：2018-01-18
发明人： Luca Fadini , Peter Manini , Claudio Pietra , Claudio Giuliano , Emanuela Lovati , Roberta Cannella , Alessio Venturini , Valentino J. Stella
IPC分类号： C07F9/6509 , C07D401/04 , C07D213/89 , C07D213/74 , A61K45/06 , A61K31/44 , A61K31/56 , A61K31/496 , A61K31/473 , A61K31/675
CPC分类号： C07F9/650952 , A61K31/44 , A61K31/473 , A61K31/496 , A61K31/56 , A61K31/675 , A61K45/06 , C07D213/74 , C07D213/89 , C07D401/04
摘要： Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor. The compounds have the general formula (I):
-
公开(公告)号：US20180193262A1
公开(公告)日：2018-07-12
申请号：US15708440
申请日：2017-09-19
发明人： Giorgio Calderari , Daniele Bonadeo , Roberta Cannella , Alberto Macciocchi , Andrew Miksztal , Thomas Malefyt , Kathleen M. Lee , Carmine Panuccio
IPC分类号： A61K9/08 , A61K47/10 , B65B7/16 , B65B55/02 , A61K9/00 , A61K47/26 , A61K47/00 , A61K31/473 , A61K47/12 , A61K47/18 , A61K47/02
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/0095 , A61K31/473 , A61K47/00 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26 , B65B7/16 , B65B55/02
摘要： The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
-
公开(公告)号：US20160317440A1
公开(公告)日：2016-11-03
申请号：US15209995
申请日：2016-07-14
发明人： Giorgio Calderari , Daniele Bonadeo , Roberta Cannella , Andrew Miksztal , Thomas Malefyt , Kathleen M. Lee
CPC分类号： A61K9/08 , A61J3/00 , A61K9/0019 , A61K9/0053 , A61K31/4178 , A61K31/473 , A61K31/4747 , A61K47/02 , A61K47/12 , A61K47/16 , A61K47/183 , A61K47/26 , B65B3/04 , B65B55/02
摘要： The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
-
公开(公告)号：US09439854B2
公开(公告)日：2016-09-13
申请号：US14793233
申请日：2015-07-07
发明人： Giorgio Calderari , Daniele Bonadeo , Roberta Cannella , Alberto Macciocchi , Andrew Miksztal , Thomas Malefyt , Kathleen M Lee
IPC分类号： A61K31/47 , A61K47/26 , A61K31/473 , A61K9/08 , A61K47/18 , A61K47/12 , A61K47/00 , A61K47/02 , A61K9/00 , B65B7/16 , B65B55/02 , A61K47/10
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/0095 , A61K31/473 , A61K47/00 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26 , B65B7/16 , B65B55/02
摘要： The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
-
公开(公告)号：US20200206249A1
公开(公告)日：2020-07-02
申请号：US16817683
申请日：2020-03-13
IPC分类号： A61K31/675 , A61P1/08 , A61K9/08 , A61K47/26 , A61K47/18 , A61K47/02 , A61K31/496 , A61K31/473 , A61K9/19 , A61K9/00
摘要： Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
-
公开(公告)号：US20150306032A1
公开(公告)日：2015-10-29
申请号：US14793233
申请日：2015-07-07
发明人： Giorgio Calderari , Daniele Bonadeo , Roberta Cannella , Andrew Miksztal , Thomas Malefyt , Kathleen M Lee
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/0095 , A61K31/473 , A61K47/00 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26 , B65B7/16 , B65B55/02
摘要： The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
摘要翻译： 本发明涉及帕洛诺司琼用于减轻化学疗法和放射治疗诱发呕吐与帕洛诺司琼的货架稳定液体制剂。 制剂特别可用于制备静脉内和口服液体药物。
-
公开(公告)号：US08729094B2
公开(公告)日：2014-05-20
申请号：US13902132
申请日：2013-05-24
发明人： Giorgio Calderari , Daniele Bonadeo , Roberta Cannella , Alberto Macciocchi , Andrew Miksztal , Thomas Malefyt , Kathleen M Lee
IPC分类号： A61K47/00
CPC分类号： A61K9/08 , A61K9/0019 , A61K9/0095 , A61K31/473 , A61K47/00 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26 , B65B7/16 , B65B55/02
摘要： The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
摘要翻译： 本发明涉及帕洛诺司琼用于减轻化学疗法和放射治疗诱发呕吐与帕洛诺司琼的货架稳定液体制剂。 制剂特别可用于制备静脉内和口服液体药物。
-
公开(公告)号：US20230172953A1
公开(公告)日：2023-06-08
申请号：US17986934
申请日：2022-11-15
IPC分类号： A61K31/675 , A61K9/08 , A61P1/08 , A61K9/00 , A61K9/19 , A61K31/473 , A61K31/496 , A61K47/02 , A61K47/18 , A61K47/26
CPC分类号： A61K31/675 , A61K9/08 , A61P1/08 , A61K9/0019 , A61K9/19 , A61K31/473 , A61K31/496 , A61K47/02 , A61K47/183 , A61K47/26
摘要： Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
-
公开(公告)号：US10717721B2
公开(公告)日：2020-07-21
申请号：US16228835
申请日：2018-12-21
发明人： Luca Fadini , Peter Manini , Claudio Pietra , Claudio Giuliano , Emanuela Lovati , Roberta Cannella , Alessio Venturini , Valentino J. Stella
IPC分类号： C07D213/74 , C07D401/04 , A61K31/496 , A61K31/56 , A61K45/06 , C07D213/89 , A61K31/44 , A61K31/473 , A61K31/675 , C07F9/6509 , A61P25/22 , A61P13/10 , A61P25/24 , A61P1/08 , A61K9/00 , A61K31/573
摘要： Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor. The compounds have the general formula (I):
-
-
-
-
-
-
-
-
-
搜索结果
33 条记录 (耗时 0.021 秒)
